Ralphey, From my reading of the article it is the fact that the patented and unpatented indications are intertwined. The attempted carve out does not separate them. It is this lack of separation (according to the article) that makes the Teva label a partial label and not a skinny label. If that is the case in GSK v Teva it should hold for Amarin. If anyone thinks I am incorrect please explain it to me. Sleven,
Market Data 
Markets 
AI
